/
Markets
Crypto
News
Forecasts
Forex Brokers
Calendars
Macro Data
About us
Commodity Prices
Currency Rates
Cryptocurrency Prices
Global Market Indices
Stock Prices
ETF Prices
Cryptocurrency Prices
Crypto Exchanges
Crypto Wallets
Cryptocurrency News
Cryptocurrency Forecasts
Commodity News
Forex News
Crypto News
Stock Market News
Economic News
Opinions
Broker News
Commodities
Forex
Crypto
Indices
Natural Gas Forecasts
Gold Forecasts
WTI Crude Oil Forecasts
S&P 500 Forecasts
Forex Brokers Reviews
Best Brokers Guides
Compare Forex Brokers
Best Forex Brokers
Best Forex Platforms
Best MT4 Brokers
Best for Trading Gold
Best Brokers in Australia
Best Brokers for Beginners
Best Brokers in UK
Brokers Promotions
Stock Brokers
Economic Calendar
Earnings Calendar
Splits Calendar
Dividends Calendar
Holiday Calendar
IPO Calendar
Stock Screener
Currency Converter
Global Macro indicators
Sovereign Credit Ratings
Global Major Indicators
Interest Rates
United States Indicators
China Indicators
Australia Indicators
Euro Area Indicators
About us
Contact Us
Terms Of Use
Become A Contributer
EUR/USD
+0.25%
Natural Gas
+0.94%
Gold
N/A
BTC
N/A
ETH
N/A
SPX
-0.46%
VIX
N/A
Economic Calendar
EUR/USD
+0.25%
Natural Gas
+0.94%
Gold
N/A
BTC
N/A
ETH
N/A
SPX
-0.46%
VIX
N/A
Economic Calendar
BTC
N/A
ETH
N/A
XRP
N/A
ADA
N/A
SOL
N/A
Review
Review
Review
Tech Giants Excel: Alphabet’s Dividend, Microsoft’s AI Growth, Snap’s Q1 Surge
about 1 hour ago
Microsoft and Alphabet Bracing for Key Earnings Release
about 3 hours ago
Pending Home Sales Increased 3.4% In March, Beating Analyst Expectations
about 7 hours ago
US GDP Growth Starts 2024 Below Expectations
about 7 hours ago
German GfK Consumer Climate Indicator Climbs to -24.2 for May
about 15 hours ago
Nasdaq Tumbles as Meta Sparks Renewed Tech Beating
about 17 hours ago
XRP Price Shows Strength Against BTC -$0.65 Rally Next?
9 minutes ago
BONK Price Forecast: What Next after Overtaking PEPE with 120% Rally?
19 minutes ago
Bitcoin (BTC) Price Forecast: $60k Reverse or $70k Rebound?
18 minutes ago
Bitcoin Price Forecast: Bullish Patterns Evolve Amidst Underlying Weakness
about 1 hour ago
Gold Price Forecast: Short-Term Bullish Momentum but Resistance Looms
about 1 hour ago
Natural Gas Price Forecast: Will Support Hold or Breakdown Continue?
about 2 hours ago
Quick Links
:
Forecasts
Economic Calendar
Commodities
Trade Now
ad
ad
Advertisement
Advertisement
home
stocks
ABBV
profile
Abbvie Inc
Follow
ABBV
(
NYSE
)
N/A
167.29
-0.51 (-0.30%)
in
:
usd
•
As of: Apr 25, 2024 15:59
UTC -4
After Market
:
166.5
-0.79 (-0.47%)
Open
168.11
High
169.24
Low
165.60
Overview
News & Analysis
Profile
Financials
Advanced Chart
History
Earnings
Dividends
About
Abbvie Inc
CEO
RichardA. Gonzalez
Headquarters
1 north waukegan road
north chicago, il 60064, united states
Auditor
Ernst & Young LLP
Employees
50,000
Share Holders
42,369
Website
www.abbvie.com
Industry
pharmaceuticals major
Sector
health technology
Company Overview
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
Abbvie Inc
Statistics
Valuation Measures
Market Capitalization
2
296.21B
Enterprise Value
342.78B
Enterprise Value/EBITDA
(ttm)
15.98
Price to Earnings Ratio
(ttm)
15.26
Price to Book
(mrq)
29.35
Price to Sales
(ttm)
5.53
Price to Cash
(ytd)
10.72
Profitability
Gross Margin
(ttm)
62.59%
Operating Margin
(ttm)
36.40%
Profit Margin
(ttm)
8.77%
Return on Equity
(ttm)
162.28%
Return on Invested Capital
(ttm)
7.23%
Return on Assets
(ttm)
14.62%
Income Statement
Revenue
(ttm)
54.32B
Revenue Per Share
(ttm)
30.75
Gross Profit
(ttm)
33.90B
EBITDA
(ttm)
3
21.45B
Net Income Avi to Common
(ttm)
4.86B
Diluted EPS
(ttm)
2.73
Share Statistics
Beta (5Y Monthly)
0.58
52-Week Change
5.57%
S&P500 52-Week Change
23.99%
S&P500 Member
Yes
Stock Optionable
Yes
Total Shares Outstanding
1
1.77B
Dividend Yield
3.66%
Float
4
1.77B
%
Held by Insiders
0.25%
%
Held by Institutions
70.23%
Balance Sheet
Total Cash
(mrq)
12.82B
Total Cash Per Share
(mrq)
7.26
Total Debt
(mrq)
59.38B
Total Debt/Equity
(mrq)
571.17%
Current Ratio
(mrq)
0.87%
Quick Ratio
(mrq)
0.76%
Book Value Per Share
(mrq)
5.89
Cash Flow
Operating Cash Flow Per Share
(ytd)
12.88
Free Cash Flow
(ytd)
22.06B
Table Key
mrq
=
Most Recent Quarter
ttm
=
Trailing Twelve Months
ytd
=
Year To Date
Footnotes
Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.
1
Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2
Market Cap is calculated using total shares outstanding and the most recent share price.
3
EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4
The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Sponsored
Sponsored
This Section / Page contains links to the 3rd party websites of our top partners from whom we may receive compensation.
Trade With A Regulated Broker